Multisociety clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period
10.1016/j.cgh.2024.10.003 · doi-reference
AGA rapid clinical practice update on the management of patients taking GLP-1 receptor agonists prior to endoscopy: communication
10.1016/j.cgh.2023.11.002 · doi-reference
Anesthesiologists’ learning curves for bedside qualitative ultrasound assessment of gastric content: a cohort study
10.1007/s12630-013-9974-y · doi-reference
Diagnostic accuracy of point-of-care gastric ultrasound
10.1213/ane.0000000000003372 · doi-reference
Gastric volume and antral area in the fasting state: a meta-analysis of individual patient data
10.1097/aln.0000000000004914 · doi-reference
Point-of-care gastric ultrasound and aspiration risk assessment: a narrative review
10.1007/s12630-017-1031-9 · doi-reference
Ultrasound assessment of gastric content and volume
10.1097/aln.0b013e3181a97250 · doi-reference
Holding vs continuing GLP-1/GIP agonists before upper endoscopy: the OCULUS Randomized Clinical Trial
10.1001/jamainternmed.2026.0027 · doi-reference
Effects of glucagon-like peptide-1 receptor agonists on upper gastrointestinal endoscopy: a meta-analysis
10.1016/j.cgh.2024.07.021 · doi-reference
Impact of GLP-1 receptor agonists on upper gastrointestinal endoscopy: an updated systematic review and meta-analysis
10.1007/s00464-025-11962-4 · doi-reference
Glucagon-like peptide-1 receptor agonist use and the risk of residual gastric contents and aspiration in patients undergoing GI endoscopy: a systematic review and a meta-analysis
10.1016/j.gie.2024.12.019 · doi-reference
Glucagon-like peptide-1 receptor agonists do not increase aspiration during upper endoscopy in patients with diabetes
10.1016/j.cgh.2024.04.038 · doi-reference
Glucagon-like peptide receptor agonists use before endoscopy is associated with low retained gastric contents: a multicenter cross-sectional analysis
10.14309/ajg.0000000000002969 · doi-reference
Effects of glucagon-like peptide-1 receptor agonists on upper endoscopy in diabetic and nondiabetic patients
10.1016/j.gie.2024.04.2900 · doi-reference
Quantified metrics of gastric emptying delay by glucagon-like peptide-1 agonists: a systematic review and meta-analysis with insights for periprocedural management
10.14309/ajg.0000000000002820 · doi-reference
Semaglutide, delayed gastric emptying, and intraoperative pulmonary aspiration: A case report
10.1007/s12630-023-02440-3 · doi-reference
The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists
10.1111/dom.14110 · doi-reference
Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: a randomized controlled trial
10.1111/dom.15802 · doi-reference
Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans
10.2337/db10-0474 · doi-reference
Glucagon-like peptide-1 receptor agonists and gastric emptying time: a systematic review and meta-analysis of prospective studies
10.1007/s12630-026-03114-6 · doi-reference
Effects of glucagon-like peptide-1(7-36)amide on antro-pyloro-duodenal motility in the interdigestive state and with duodenal lipid perfusion in humans
10.1136/gut.46.5.622 · doi-reference
Vagally mediated effects of glucagon-like peptide 1: in vitro and in vivo gastric actions
10.1113/jphysiol.2009.175067 · doi-reference
An inter-organ neural circuit for appetite suppression
10.1016/j.cell.2022.05.007 · doi-reference
Glucagon-like peptide-1 inhibits prandial gastrointestinal motility through myenteric neuronal mechanisms in humans
10.1210/jc.2017-02006 · doi-reference
